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Surgical treatment of pancreatic endocrine tumors in
multiple endocrine neoplasia type 1
Marcel Cerqueira Cesar Machado
Faculdade de Medicina da Universidade de Sa˜o Paulo, Department of Surgery, Sa˜o Paulo/SP, Brazil.
Surgical approaches to pancreatic endocrine tumors associated with multiple endocrine neoplasia type 1 may differ
greatly from those applied to sporadic pancreatic endocrine tumors. Presurgical diagnosis of multiple endocrine
neoplasia type 1 is therefore crucial to plan a proper intervention. Of note, hyperparathyroidism/multiple endocrine
neoplasia type 1 should be surgically treated before pancreatic endocrine tumors/multiple endocrine neoplasia type
1 resection, apart from insulinoma. Non-functioning pancreatic endocrine tumors/multiple endocrine neoplasia
type 1 .1 cm have a high risk of malignancy and should be treated by a pancreatic resection associated with
lymphadenectomy. The vast majority of patients with gastrinoma/multiple endocrine neoplasia type 1 present with
tumor lesions at the duodenum, so the surgery of choice is subtotal or total pancreatoduodenectomy followed by
regional lymphadenectomy. The usual surgical treatment for insulinoma/multiple endocrine neoplasia type 1 is
distal pancreatectomy up to the mesenteric vein with or without spleen preservation, associated with enucleation of
tumor lesions in the pancreatic head. Surgical procedures for glucagonomas, somatostatinomas, and vipomas/
multiple endocrine neoplasia type 1 are similar to those applied to sporadic pancreatic endocrine tumors. Some of
these surgical strategies for pancreatic endocrine tumors/multiple endocrine neoplasia type 1 still remain
controversial as to their proper extension and timing. Furthermore, surgical resection of single hepatic metastasis
secondary to pancreatic endocrine tumors/multiple endocrine neoplasia type 1 may be curative and even in multiple
liver metastases surgical resection is possible. Hepatic trans-arterial chemo-embolization is usually associated with
surgical resection. Liver transplantation may be needed for select cases. Finally, pre-surgical clinical and genetic
diagnosis of multiple endocrine neoplasia type 1 syndrome and localization of multiple endocrine neoplasia type 1-
related tumors are crucial for determining the best surgical strategies in each individual case with pancreatic
endocrine tumors.
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INTRODUCTION
Pancreatic neuroendocrine tumors (PETs) originate from
pancreatic islet tissue. Pancreatic endocrine tumors may
produce clinical symptoms as a result of excessive produc-
tion of one or more hormones such as gastrin, insulin,
somatostatin, glucagon, and vasoactive intestinal polypep-
tide (functioning PETs) or may be silent, producing only
pancreatic polypeptides (non-functioning PETs).
Multiple endocrine neoplasia type 1 (MEN1) is a complex
inherited condition, which may comprise up to 20 different
types of endocrine and non-endocrine tumors, although the
three most prevalent conditions are hyperparathyroidism,
PETs, and pituitary tumors (1). MEN1 leads to increased
morbidity and mortality rates, mainly as a result of PETs
and thymic carcinoids (1,2).
PETs/MEN1 VERSUS S-PETs
The PETs associated with MEN1 (PETs/MEN1) may differ
markedly from sporadic PETs (S-PETs) and are characterized
by: (i) an earlier disease onset; (ii) a propensity to present
higher risk for malignancy; (iii) multiple tumor lesions
scattered throughout the pancreas and duodenum, instead
of a single pancreatic nodule as in S-PETs; (iv) variable
hormone production; (v) most patients having a familial
history of PETs; and (vi) most cases (,90%) harboring an
inactivating germline mutation in theMEN1 tumor suppres-
sor gene (1). Based on the clinical differences between PETs/
MEN1 and S-PETs, distinct surgical approaches are used for
each of these conditions.
Surgical treatment of tumor lesions in PETs/MEN1 may
be controversial but its rationale is based on cure of the
clinical syndrome and avoidance of malignant tumor
progression (2).
In MEN1 patients, primary hyperparathyroidism is fre-
quently the first clinical manifestation and is usually the first
condition to be surgically treated. This was recently verified
in a large MEN1 family caused by a founding MEN1 gene
mutation (3,4). The reduction in calcium/parathyroid hor-
mone serum levels after total parathyroidectomy followed by
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parathyroid auto-implant in patients withMEN1 is beneficial
to the metabolic status, but it also leads to decreasing
secretion of several hormones, such as gastrin, which in turn
may cause a significant improvement of the clinical symp-
toms secondary to the hormonal excess (5–7). Parathyroidec-
tomy in MEN1 should therefore be performed before
operation for PETs, apart from in insulinoma.
As mentioned, surgical strategies applied to PETs/MEN1
differ greatly from the usual approaches used in patients
with S-PETs. Clinical and genetic diagnosis of MEN1 should
be made or ruled out before surgery in each patient with
MEN1, as reported previously (3,8). This procedure will
allow the identification of the best surgical approach to each
individual case of PET, which may potentially lead to lower
morbidity and mortality rates in patients with PET-
associated MEN1.
We also performed methodical screening for the MEN1
tumor suppressor gene in our MEN1 families, which should
allow the early diagnosis and treatment of MEN1 in
relatives carrying MEN1 germline mutations and a trend
towards lower morbidity rates (9).
PREOPERATIVE EVALUATION
Computed tomography, magnetic resonance imaging,
and ultrasonography can miss PETs,1 cm. Octreotide
scintigraphy is an efficient diagnostic tool but this depends
on the size of the lesion and the presence of somatostatin
receptors in the tumor cells. Recently, gallium-labeled
somatostatin analog peptide has been used to detect
MEN1-related tumors (10).
Endoscopic ultrasonography is the most useful tool for
tumor diagnosis and localization in PETs/MEN1, as well as
for depiction of the anatomic relationship with the main
pancreatic duct, which is important for the proper surgical
treatment. Endoscopic ultrasonography is able to detect
PETs,1 cm, allowing early diagnosis (Figure 1). Invasive
techniques for the diagnosis and localization of gastrinomas
or insulinomas have been reported, although their accuracy
has not been reproduced in all centers (11).
Furthermore, in our experience, intraoperative palpation,
inspection, and ultrasonography are efficient tools to
localize most lesions (11).
NON-FUNCTIONING PETS
In a recent study, Goudet et al. (12) verified that PETs,
including the non-functioning PETs, and thymic carcinoids
are frequent causes of death in patients with MEN1.
At diagnosis, non-functioning PETs are frequently malig-
nant, usually larger and with a worse prognosis than
functioning PETs. Tumor size was positively correlated with
malignancy and lesions .2.0 cm have been reported to have
a higher risk for malignancy (13). In addition, other authors
showed that non-functioning PETs with diameters .1.0 cm
are already prone to metastasize (14). Based on these
findings, pancreatic resection associated with lymphadenect-
omy has been recommended in these cases (14). Moreover, as
liver metastases are frequently found in PETs.1.0 cm, these
tumors should be carefully investigated and operated on
as soon as possible (12,14). Concordantly, extended distal
pancreatectomy associated with enucleation of PETs.1 cm
located at the pancreatic head has also been recommended, in
an attempt to prevent liver metastases (15).
Conversely, total pancreatectomy, associated or not with
duodenectomy, has not been indicated because of the
possible decrease in the patient’s quality of life, although
this surgical intervention may be used in selected PET/
MEN1 patients (16).
GASTRINOMAS
The vast majority of sporadic gastrinomas are represented
by single tumors located at the pancreas and the current
surgical approach to these lesions is tumor enucleation.
Conversely, the majority of gastrinomas/MEN1 are
multiple, asynchronic tumors mostly spread throughout
the duodenum and less frequently found in the pancreas.
These frequently malignant tumors (,60%) are mostly
associated with multiple and small gastric carcinoids (1,3,14).
Controversies related to the surgical approach to gastri-
noma/MEN1 may exist and are mostly related to the timing
and extension of the surgical procedure. These tumors
usually have an unpredictable course, difficult preoperative
localization and present as multiple duodenal tumors.
Although PETs usually lead to limited survival, some
patients with metastatic PETs may survive for long periods
of time with clinical treatment.
Some authors recommend surgical treatment only for
cases with gastrinomas/MEN1 .3.0 cm, whereas others
indicate an early surgical intervention for all gastrinoma/
MEN1 patients, as soon as the diagnosis is made (14,17–19).
This controversy may be related to the fact that there
appear to be two different patterns of gastrinomas in MEN1
patients: the first tend to have an indolent course with or
without metastasis, whereas the second pattern is charac-
terized by rapid tumor progression. Although there are no
definite markers for the adequate identification of these two
potential gastrinoma subsets, the aggressiveness of these
tumors could be evaluated by the following parameters:
serum levels of gastrin, tumor histological differentiation,
Ki-67 positivity, a high mitotic number, and the presence of
progesterone receptors, as reported recently (19).
Pancreatoduodenectomy with regional
lymphadenectomy
Limited surgical resection with excision of duodenal
tumors, excision of pancreatic cephalic lesions, and distal
Figure 1 - Endoscopic ultrasonography. Arrow shows a small
pancreatic neuroendocrine tumor.
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pancreatectomy have been proposed as surgical alternatives
for the treatment of gastrinomas/MEN1 (18). However, as
reported in the literature and also supported by our own
observations, such surgical approaches may be frequently
followed by a low cure rate and a high recurrence rate.
Considering that most gastrinomas/MEN1 are located
in the duodenum, a more radical surgical intervention is
proposed for these patients including pancreatoduodenect-
omy followed by regional lymphadenectomy (17,20).
Pancreatoduodenectomy may be performed with pylorus
preservation or including gastric resection (Whipple’s
technique). It is important to actively search for the presence
of duodenal tumors even in the first 1–2 cm of the
duodenum. Despite the functional advantages of the
pylorus-preserving technique, it may be safer to perform
Whipple’s procedure in gastrinoma/MEN1 patients.
In some cases, total pancreatectomy is the treatment of
choice, in an attempt at the complete removal of all tumor
lesions (Figure 2). Radical resection may also be considered
because the sensitivity of the methods used in detecting
tumor lesions is low. Also, intraoperative gastrin measure-
ments may be helpful to improve our capacity for
determining the extent of resection (14).
INSULINOMAS
For sporadic insulinomas the diagnosis, preoperative
localization, and surgical approach are well established
and surgery consists of tumor enucleation (11).
In insulinoma/MEN1, the surgical management is com-
pletely different because in this condition, there are multiple
tumors spread throughout the pancreas, including tumors
with potential for malignancy. Enucleation is not the best
treatment for these lesions because high incidences of
recurrence or persistence of hypoglycemia have been
reported after simple tumor enucleation.
The current therapeutic surgery for insulinoma/MEN1 is
distal pancreatectomy up to the mesenteric vein with or
without spleen preservation, associated with enucleation of
lesions located in the head of the pancreas (Figure 3). This
procedure frequently has few postoperative complications
(11,14). However, in cases with major involvement of the
pancreatic head, a pylorus-preserving pancreatoduodenect-
omy should be performed. Higher recurrence rates have
been observed after surgical resection of insulinoma/
MEN1, compared with sporadic insulinomas (21–23).
The confirmation of complete tumor removal is of
paramount importance. Intraoperative determinations of
serum glucose and insulin levels for evaluating the presence
of tumor tissue left behind have been reported but their
accuracy is low.
In our experience, intraoperative ultrasonography asso-
ciated with monitoring of serum levels of glucose/insulin is
a useful tool to confirm the completeness of tumor resection
(11).
GLUCAGONOMAS, SOMATOSTATINOMAS, AND
VIPOMAS
These three types of tumors occur rarely in MEN1
patients. Specific guidelines for the surgical treatment of
these lesions are not currently available so the surgical
procedures usually follow basically the same criteria used
for non-functioning or functioning PETs described above.
Most of these tumors are malignant and metastatic lesions
are usually present in PETs.3 cm. Radical surgical resec-
tion is the proposed treatment for these latter lesions.
HEPATIC METASTASES
As stated by the National Comprehensive Cancer
Network guideline and the consensus guidelines by the
European NET Study Group: surgical treatment is the most
effective therapeutic method with which to treat hepatic
metastases from PETs/MEN1 (24–26).
Surgical resection of a single hepatic metastasis may be
curative. Even in cases with multiple liver metastases,
surgical resection is possible. In this latter situation, portal
vein embolization is used as a strategy to increase the left
lobe size and metastatic lesions can then be removed in a
first-stage operation (Figure 4). This procedure is useful as
cytoreductive surgery in patients with a clinical syndrome
that is refractory to clinical treatment. Hepatic trans-arterial
chemo-embolization can also be used as an ablation tool,
Figure 2 - Octroscan showing gastrinomas disseminated through-
out the pancreas. Total pancreatectomy was performed in this
case.
Figure 3 - Distal pancreatectomy in a patient with insulinomas
associated with multiple endocrine neoplasia type 1. Eleven
small tumors were found. Serum glucose returned to normal
after surgery.
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usually associated with surgical resection. Liver transplan-
tation may also be used in selected patients (27).
CONCLUSION
Surgical strategies applied to PETs/MEN1 may greatly
differ from those used in patients with S-PETs. Clinical and
genetic diagnosis of MEN1 should be performed or ruled
out before surgery in all patients presenting with apparently
sporadic PETs. The presurgical differential diagnosis
between S-PETs and PETs/MEN1 will allow surgeons to
choose the best surgical approach to each individual case,
aiming to lower morbidity and mortality rates, or even
obtain cure, in patients with PETs associated with MEN1.
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